The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

Since the first reports of a novel severe acute respiratory syndrome (SARS)-like coronavirus
in December 2019 in Wuhan, China, there has been intense interest in understanding how …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape,–, have activity
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …

Our understanding of the still unfolding severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) pandemic would have been extremely limited without the study of the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of
coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the …

The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …

Host–pathogen interactions and pathogen evolution are underpinned by protein–protein
interactions between viral and host proteins. An understanding of how viral variants affect …

A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to
control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have …

The mode of acquisition and causes for the variable clinical spectrum of coronavirus disease
2019 (COVID-19) remain unknown. We utilized a reverse genetics system to generate a …

The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused
significant public health concerns. Recently, ACE2 was reported as an entry receptor for …